Manila Times Business
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, June 02, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that on June 1, 2026, the Compensation Committee of Praxis’ Board of Directors granted restricted stock unit awards covering an aggregate of 2,754 shares of its common stock to thirteen new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 202
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Keystone Acquisition Corp. Announces Pricing of $250 Million Initial Public Offering
2h ago
Moderna Launches Moderna Direct with "eCommerce Powered by FFF Enterprises™”
2h ago
ATN International, Inc. Completes Initial Closing on the Sale of its Towers and Updates 2026 Outlook
2h ago
Neuronetics Appoints Robert Greene as Senior Vice President Sales
2h ago